Institut Curie, Stress and Cancer Laboratory, Equipe Labélisée par la Ligue Nationale Contre le Cancer, PSL Research University, 26, Rue d'Ulm, F-75248, Paris, France.
Inserm, U830, 26, Rue d'Ulm, F-75005, Paris, France.
Nat Commun. 2024 Apr 1;15(1):2806. doi: 10.1038/s41467-024-47068-z.
Although heterogeneity of FAP+ Cancer-Associated Fibroblasts (CAF) has been described in breast cancer, their plasticity and spatial distribution remain poorly understood. Here, we analyze trajectory inference, deconvolute spatial transcriptomics at single-cell level and perform functional assays to generate a high-resolution integrated map of breast cancer (BC), with a focus on inflammatory and myofibroblastic (iCAF/myCAF) FAP+ CAF clusters. We identify 10 spatially-organized FAP+ CAF-related cellular niches, called EcoCellTypes, which are differentially localized within tumors. Consistent with their spatial organization, cancer cells drive the transition of detoxification-associated iCAF (Detox-iCAF) towards immunosuppressive extracellular matrix (ECM)-producing myCAF (ECM-myCAF) via a DPP4- and YAP-dependent mechanism. In turn, ECM-myCAF polarize TREM2+ macrophages, regulatory NK and T cells to induce immunosuppressive EcoCellTypes, while Detox-iCAF are associated with FOLR2+ macrophages in an immuno-protective EcoCellType. FAP+ CAF subpopulations accumulate differently according to the invasive BC status and predict invasive recurrence of ductal carcinoma in situ (DCIS), which could help in identifying low-risk DCIS patients eligible for therapeutic de-escalation.
尽管已经在乳腺癌中描述了 FAP+癌症相关成纤维细胞(CAF)的异质性,但它们的可塑性和空间分布仍知之甚少。在这里,我们分析轨迹推断,单细胞水平上的去卷积空间转录组学,并进行功能测定,以生成乳腺癌(BC)的高分辨率综合图谱,重点关注炎症和成肌纤维(iCAF/myCAF)FAP+CAF 簇。我们确定了 10 个空间组织的 FAP+CAF 相关细胞生态位,称为 EcoCellTypes,它们在肿瘤内的定位存在差异。与它们的空间组织一致,癌细胞通过 DPP4 和 YAP 依赖性机制促使与解毒相关的 iCAF(Detox-iCAF)向免疫抑制性细胞外基质(ECM)产生的成肌纤维(ECM-myCAF)转化。反过来,ECM-myCAF 使 TREM2+巨噬细胞、调节性 NK 和 T 细胞极化,从而诱导免疫抑制性 EcoCellTypes,而 Detox-iCAF 则与免疫保护性 EcoCellType 中的 FOLR2+巨噬细胞相关。根据侵袭性 BC 状态,FAP+CAF 亚群的积累情况不同,并预测导管原位癌(DCIS)的侵袭性复发,这有助于识别有资格进行治疗降级的低危 DCIS 患者。